Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement

Ludger Klimek 1 | Marek Jutel 2 | Cezmi Akdis 3 | Jean Bousquet 4,5,6,7 | Mübeccel Akdis 3 | Claus Bachert 8 | Ioana Agache 9 | Ignacio Ansotegui 10 | Anna Bedbrook 7 | Sinthia Bosnic-Anticevich 11 | G. Walter Canonica 12,13 | Tomas Chivato 14 | Alvaro A. Cruz 15,16 | Wiencyslawa Czarlewska 17 | Stefano Del Giacco 18 | Hui Du 19 | Joao A. Fonseca 20,21,22,23 | Yadong Gao 24 | Tari Hahtela 25 | Karin Hoffmann-Sommergruber 26 | Juan-Carlos Ivancevich 27 | Nikolai Khaltaviev 28 | Edward F. Knol 29 | Piotr Kuna 30 | Desiree Larenas-Linnemann 31 | Erik Melén 32 | Joaquim Mullol 33,34 | Robert Naclerio 35 | Ken Ohta 36 | Yoshitaka Okamoto 37 | Liam O’Mahony 38 | Gabrielle L. Onorato 39 | Nikos G. Papadopoulos 39 | Ruby Pawankar 40 | Oliver Pfaar 41 | Boleslaw Samolinski 42 | Jurgen Schwarze 43 | Sanna Toppila-Salmi 25 | Mohamed H. Shamji 44 | Maria Teresa Ventura 45 | Arunas Valiulis 46,47 | Arzu Yorgancioglu 48 | Paolo Matricardi 39 | Torsten Zuberbier 50,51 | the ARIA-MASK study group

1 Center for Rhinology and Allergology, Wiesbaden, Germany
2 Department of Clinical Immunology, ALL-MED Medical Research Institute, Wroclaw Medical University, Wroclaw, Poland
3 Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland
4 Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
5 Department of Dermatology and Allergy, Berlin Institute of Health, Comprehensive Allergy Center, Berlin, Germany
6 University Hospital, Montpellier, France
7 MACVIA-France, Montpellier, France
8 ENT Department, Upper Airways Research Laboratory, Ghent University Hospital, Ghent, Belgium
9 Transylvania University Brasov, Brasov, Romania
10 Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain
11 Woolcock Institute of Medical Research, Woolcock Emphysema Centre and Sydney Local Health District, University of Sydney, Glebe, NSW, Australia
12 Personalized Medicine, Asthma and Allergy - Humanitas Clinical and Research Center – IRCCS, Rozzano (MI), Italy
13 Department of Biomedical Sciences - Humanitas University - Pieve Emanuele (MI), Italy
14 School of Medicine, University CEU San Pablo, Madrid, Spain
15 ProAR – Nucleo de Excelencia en Asma, Federal University of Bahia, Salvador, Brazil
16 WHO GARD Planning Group, Salvador, Brazil

Ludger Klimek, Marek Jutel, Cezmi Akdis, Jean Bousquet, Mübeccel Akdis are participated equally to the paper.

1 Member of ARIA and MASK boards
2 Member of EAACI board of officers

ARIA-MASK study group details are given in Appendix 1

© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
The current COVID-19 pandemic influences many aspects of personal and social interaction, including patient contacts with health care providers and the manner in which allergy care is provided and maintained. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on inducing an appropriate immune response in the allergic patient. This manuscript outlines the EAACI recommendations regarding AIT during the COVID-19 pandemic and aims at supporting allergists and all physicians performing AIT in their current daily practice with clear recommendations on how to perform treatment during the pandemic and in SARS-CoV-2 infected patients.
1 | INTRODUCTION

The current COVID-19 pandemic influences many areas of social life, medical treatments and the way allergy diagnosis and treatment is performed. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on immunological effects on the diseased patient. This manuscript outlines the EAACI recommendations regarding AIT during the COVID-19 pandemic and aims at supporting allergists and all physicians performing AIT in their current daily practice with clear recommendations on how to perform treatment during the pandemic and in SARS-CoV-2 infected patients.

1.1 | Coronavirus disease 2019 (COVID-19)

On March 11, 2020, the World Health Organization (WHO) declared a pandemic of an infectious disease recently referred to as “coronavirus disease 2019” (COVID-19). Currently, COVID-19 is spreading rapidly across the globe. COVID-19 is caused by a novel strain of human coronaviruses, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), named by the International Committee on Taxonomy of Viruses (ICTV). SARS-CoV-2 was first detected in a cluster of patients with pneumonia in December 2019 in Wuhan, China.1,2 SARS-CoV-2 is a Betacoronavirus of the subgenus Sarbecovirus and the subfamily Orthocoronavirinae. It can be isolated from human samples obtained from respiratory secretions, nasal and pharyngeal smears and isolated on cell cultures.1,2 SARS-CoV-2 is the 7th member of the coronavirus family able to infect humans. It differs from the Middle East respiratory syndrome coronavirus (MERS-CoV), the severe acute respiratory syndrome coronavirus (SARS-CoV), and viruses responsible for the common cold (229E, OC43, NL63, and HKU1).3 Coronaviruses are zoonotic: they can be transmitted between animals and humans.

COVID-19 presents with many different clinical manifestations, ranging from asymptomatic cases to mild and severe disease, with or without pneumonia.4

Common signs of COVID-19 are respiratory problems, fever, cough, shortness of breath, and difficulties in breathing. Other signs of viral airway infection may include nasal symptoms and sore throat. In more severe cases, infection with COVID-19 can cause pneumonia, severe acute respiratory syndrome, kidney failure, and even death.4-6 In the published scientific literature on COVID-19, higher age, chronic respiratory diseases, diabetes mellitus, coronary artery disease, and immunodeficiency of different origins are listed as risk factors for severe illness, hospitalization, and death.4-6,8

As COVID-19 is caused by a newly identified viral strain, there are no therapeutics proved to be effective in clinical trials or vaccines, so far, and there is presumed to be no pre-existing immunity in the population.9 In most instances, coronaviruses are believed to be transmitted through large respiratory droplets from person to person, through inhalation or deposition on mucosal surfaces. Other routes implicated in the transmission of coronaviruses include contact with contaminated fomites and inhalation of aerosols produced during aerosol-generating procedures, such as sneezing or coughing. The SARS-CoV-2 virus has been detected in respiratory, fecal, and blood specimens.9 The highest risk of healthcare-associated transmission occurs in the absence of standard precautions, when primary infection prevention and control measures for respiratory infections are not in place, and when handling patients whose COVID-19 diagnosis is yet to be confirmed. Since airborne transmission is possible, we recommend a cautious approach because of possible transmission through aerosols.11,12

More disease background information is available online from the European Centre for Disease Prevention and Control (ECDC),13 WHO,14 and the ECDC’s Rapid Risk Assessment.9

1.2 | Allergen-specific immunotherapy (AIT)

AIT is the only disease-modifying therapy that confers a long-term clinical benefit for allergic airway diseases such as in allergic bronchial asthma or allergic rhinoconjunctivitis and other allergic conditions.15 Since its16 emergence over one hundred years ago (1911), AIT is an established and internationally recognized procedure for the causal treatment of immediate-type allergic reactions (type I allergy) and associated diseases.

AIT induces an immune tolerance responses against the allergen in sensitized patients.17

Systematic reviews and meta-analyses have confirmed that AIT is effective in reducing symptoms together with rescue medication in patients with allergic asthma18 and allergic rhinoconjunctivitis.19

This applies to both subcutaneous immunotherapy (SCIT)20,21 and sublingual immunotherapy (SLIT), liquid drops or tablets placed under the tongue.22

The reduced risk of developing asthma in patients with allergic rhinitis is another advantage of AIT. This is still under debate but was demonstrated to be effective at least in the short term.23,24 AIT is also effective in patients with IgE-mediated food allergy23-26 and insect venom allergy.27 Moreover, analyses by the European Academy of Allergy and Clinical Immunology (EAACI) demonstrated the cost-effectiveness of this disease-modifying therapy option.28,30

1.3 | AIT and viral infections

Even though it is well established that allergic airway diseases are associated with an increased risk of infection, little is known about the potential influence of viral infections on AIT.31
In a prospective and comparative clinical study, Ahmetaji et al. found no significant difference in the efficacy or in the improvement of symptoms of allergic asthma patients under subcutaneous allergen-specific immunotherapy with or without symptomatic influenza, nor in the standard chemical and hematology parameters and different cytokines during a one-year follow-up. These preliminary data suggest that SCIT in influenza-infected patients is safe and well-tolerated.

Lemoli et al. evaluated the safety and clinical effectiveness of sublingual grass tablet immunotherapy in a group of HIV-positive patients with allergic rhinitis under antiretroviral HIV therapy. HIV infection has been regarded as a relative contraindication for AIT. Highly active antiretroviral treatment has improved the immune function and life expectancy in HIV-infected patients whose respiratory allergic incidence is similar to that of the general population. Clinical efficacy data showed a significant improvement in SLIT-treated patients compared to controls but no considerable alteration of peripheral T CD4 lymphocyte cell counts and HIV viral load in either group. These data show that SLIT therapy in viro-immunological controlled HIV-positive patients is efficacious, safe, and well-tolerated.

Cytomegalovirus (CMV) was shown to enhance the allergenic potential of otherwise poorly allergenic environmental protein antigens in a mouse model of airway co-exposure to CMV and ovalbumin (OVA). In contrast, immune reactions to virus-like-particles (Vlp) may enforce the immune responses in AIT and may even be used as AIT adjuvants for inhalational and food (peanut) allergen in the near future.

With the limited experimental data available so far, it seems that patients with allergic rhinitis did not develop additional distinct symptoms and more severe courses than other patients. Allergic children showed a mild course, similar to other children.

2 | IMMUNE MECHANISMS IN AIT AND COVID-19—DIFFERENCES AND SIMILARITIES

AIT aims to induce allergen-specific immune tolerance in allergy patients by using multiple mechanisms including T cells, B cells, intramucosal lymphoid cells (ILC), and effector cells, such as eosinophils, mast cells, and basophils. One of the main changes is the development of a T and B regulatory cell response and their suppressive cytokines such as IL-10 and TGF-β and surface molecules such as CTLA-4 and PD1, all of which form a suppressive milieu. This immune regulatory response is taking place in targeted antigen/-allergen-specific T and B cells but does not affect the whole immune system and does not cause any systemic immune deficiency. T-cell responses in severe COVID-19 are represented with lymphopenia that is mainly affecting memory T lymphocytes. Both CD4 and CD8 T cells decrease; however, this change is more pronounced in CD8+ T cells. Cytotoxic T lymphocytes and NK cells in patients infected with SARS-CoV-2 are essential for an appropriate anti-viral response. A recent study suggests that patients show functional exhaustion of cytotoxic T lymphocytes associated with SARS-CoV-2 infection. The total number of NK and CD8 + T cells was markedly decreased in patients with SARS-CoV-2 infection. This may cause a disruption of anti-viral immunity and may play a role in the pathogenesis and severity of COVID-19.

AIT significantly decreases allergen-specific Th2 cells in circulation and reduces the general type2 response by decreasing Th2 cells and type 2 ILCs. COVID-19 does not significantly increase in severity in allergic patients, with conditions such as rhinitis, urticaria, and atopic dermatitis. It has not been demonstrated if there is a switch between TH1 and TH2 cells in COVID-19, but there are developing data that disease severity is linked to a systemic Th1 response and inflammasome activation together with a cytokine storm. Similar to SARS and MERS, a cytokine storm is a common feature of severe COVID-19 cases and a major reason for acute respiratory distress syndrome (ARDS) and multi organ failure. Several levels of evidence suggest that the rapid COVID-19 mortality might be due to a virus-activated “cytokine storm syndrome”. In a study of 41 hospitalized severe COVID-19 patients, high levels of proinflammatory cytokines were observed including IL-2, IL-7, IL-10, G-CSF, IP-10, MCP-1, MIP-1A, and TNFa.

AIT changes the cellular composition and inflammatory mediators in the affected organs, for example in the nose in allergic rhinitis. Eosinophils and their inflammatory mediators decrease in allergic rhinitis in the nose during AIT. In COVID-19, systemic eosinopenia was observed in 52.9% of the patients. Decreased blood eosinophil counts correlate positively with lymphocyte counts in severe (r = 0.486, P < .001) and nonsevere (r = 0.469, P < .001) patients after hospital admission. The reasons and mechanisms of systemic eosinopenia remain to be investigated.

In AIT, reduced eosinophil counts and regulation of specific TH2 response is only seen after several years of continuous therapy. This supports that AIT is not going to interfere with viral infections. AIT has a clear desensitization effect on effector cells. This effect is antigen specific and acts early during the course of AIT. Mast cells are not considered to be relevant in viral infection response. Allergen-specific antibody levels change in the course of AIT with decreased specific IgE in the long run and a relatively rapid increase in specific IgG1 and IgG4. In COVID-19, like many viral infections, SARS-CoV-2-specific IgM increases in the acute phase followed by specific IgG.

Overall, the COVID-19 immunological mechanisms seem to be similar to SARS and MERS and also to severe influenza infections. An appropriate anti-viral immune response should develop with cytotoxic T cells and IgM and IgG antibodies, whereas a very strong uncontrolled immune response as in a cytokine storm becomes detrimental (Table 1).

3 | PREVENTING ALLERGY FACILITIES AND CONTROL MEASURES IN AIT

We recommend using the infection prevention and control measures in any patient undergoing AIT according to ECDC and WHO. This implies that the recommended infection prevention and control measures of
individual regions or countries should be followed, including those this document, as well as the procedures for reporting and for the transfer of persons under investigation and of probable/confirmed COVID-19 cases.

Those feeling ill with typical respiratory symptoms should be encouraged to contact healthcare services by telephone or E-Health/telemedicine/online to seek medical advice (triage). This will reduce the number of people with symptoms of COVID-19 that have contact with the Allergy center healthcare personnel.13,49

Allergy services and primary care staff, including physicians, nursing, and administrative staff with patient contact, should be aware of the following; (a) the current COVID-19 epidemiologic situation in their country and globally; (b) known risk factors for infections; (c) clinical symptoms and signs of COVID-19; (d) recommended infection prevention and control measures in their region or country, including those in this document; and (e) procedures for reporting and for the transfer of persons under investigation and of probable/confirmed cases.

Appropriate personal protective equipment (PPE) should be available onsite for all personnel at the point-of-care to provide standard, contact, and droplet protection.

In each Allergy facility, a dedicated member of staff (e.g., head doctor/nurse) should lead the COVID-19 preparedness and implement relevant infrastructure and control measure policies.

Signs should be posted at all entrance doors listing the main symptoms compatible with COVID-19 (fever, cough, and shortness of breath) and informing visitors with any of these symptoms not to enter the Allergy Unit. Everyone within the Allergy clinic and all those entering the practice should adopt appropriate hand hygiene measures, using soap and water, or an alcohol-based handrub.

Based on a case-by-case risk assessment, the use of PPE for AIT should be considered. With the current knowledge on the transmission of COVID-19, in which respiratory droplets seem to play a significant role (although airborne transmission cannot be ruled out at this stage), and taking into consideration the possible shortage of PPE in healthcare settings due to the increasing number of COVID-19 patients, the suggested set of PPE for droplet, contact, and airborne transmission (gloves, goggles, gown, and FFP2/FFP3 respirator) can be adapted for the clinical assessment of suspected COVID-19 cases. If available, a surgical mask should be provided for patients with respiratory symptoms (e.g., cough).50

Healthcare workers performing aerosol-generating procedures (AGP), such as swabbing,50 should wear the suggested PPE set for the prevention of droplet, contact, and airborne transmission (gloves, goggles, gown, and FFP2/FFP3 respirator).51

To maximize the use of PPE if there is an insufficient supply, staff should be assigned to carry out procedures, or a procedure, in designated areas.52

### 4 | MANAGING AIT DURING THE COVID-19 PANDEMIC

AIT is a treatment that requires recurrent doctor/nurse/patient contact over a more extended period, for example, 3 years.

In SCIT, injections are administered with daily, weekly (up dosing phase), or monthly (continuation phase) intervals.

In SLIT, the initiation is given in allergy clinics or in a doctor’s office, while continuation is performed by patients themselves with regular control visits.

Each SCIT or SLIT product needs approval by the competent authority. It must contain information on how to use the AIT product for patients, allergologists, and nurses. For most products authorized in Europe, instructions for use recommend that patients experiencing an acute respiratory tract infection should temporarily discontinue AIT treatment until the infection is resolved. We recommend taking similar action in COVID-19. Confirmed cases should discontinue AIT, both SCIT and SLIT, independent of disease severity, until the symptoms have completely resolved and/or an adequate quarantine has been performed. The possibility of expanding injection intervals in the continuation phase may be beneficial. In patients having recovered from COVID-19 or who are found to have a sufficient SARS-CoV-2 antibody response after (asymptomatic) disease,14 AIT can be started or continued as planned.

AIT can also be started or continued as usual in patients without clinical symptoms and signs of COVID-19 or other infections and without a history of exposure to SARS-CoV-2 or contact to COVID-19 confirmed individuals within the past 14 days.

---

### TABLE 1 Immunological characteristics of AIT and COVID-19

| Immunological changes       | AIT                                                                 | COVID-19                                           |
|-----------------------------|---------------------------------------------------------------------|----------------------------------------------------|
| T-cell responses            | Suppression of TH2 cells, induction of Treg and TH1 cells           | Lymphopenia in severe cases                        |
| CD8 + T cells               | There is no major change                                            | Severe lymphopenia is observed in CD8 + T cells    |
| TH1-TH2 responses           | AIT decreases allergen-specific Th2 responses in circulation and in the nose | Severe disease shows a systemic severe inflammatory response with a cytokine storm |
| Eosinophils                 | Decrease in their numbers and mediators in the nose                | Systemic decrease in their numbers in more than half of the patients. |
| Specific antibody levels    | Allergen-specific IgE decreases in the late course, with an early increase in specific IgG4 | In the acute phase, virus-specific IgM increases followed by virus-specific IgG during convalescence. |

---

KLIMEK ET AL
SLIT offers the possibility of administration at home, thus avoiding the need to travel to or stay in an allergy clinic or doctor’s office, which would be associated with a risk of infection.

5 | RECOMMENDATIONS IN NONINFECTED INDIVIDUALS DURING COVID-19 PANDEMICS OR RECOVERED PATIENTS AFTER COVID-19 INFECTION

Interrupting subcutaneous immunotherapy is not advised. Especially in potentially life-threatening allergies, such as venom allergy, SCIT should be continued regularly. The possibility of expanding injection intervals in the continuation phase should be checked and may be beneficial.

Interrupting sublingual immunotherapy is not advised. Supply the patient with sufficient medication for a minimum of a 14-day quarantine.

Both subcutaneous and sublingual immunotherapy can be continued in the current COVID-19 pandemic, in any asymptomatic patient without suspicion of SARS-CoV-2 infection and/or contact with SARS-CoV-2 positive individuals, in any patient with a negative test result (RT-PCR) or in any patient after an adequate quarantine or with detection of serum IgG to SARS-CoV-2 without virus-specific IgM.

Preparedness of your Allergy clinic is imperative when coping with COVID-19. Follow WHO guidelines and advise staff accordingly.

These recommendations are conditional since there is a paucity of data and they should be revised regularly with incoming new information on COVID-19.

6 | RECOMMENDATIONS IN COVID-19 DIAGNOSED CASES OR SUSPECTED FOR SARS-COV-2 INFECTION

Interrupting subcutaneous immunotherapy is advised.

Interrupting sublingual immunotherapy is advised.

Both subcutaneous and sublingual immunotherapy should be discontinued in symptomatic patients with exposure to or contact with SARS-CoV-2-positive individuals, or patients with positive test results (RT-PCR).

CONFLICT OF INTEREST

LK declares grants and/or personal fees from Allergopharma, MEDA/Mylan, LETI Pharma, Sanofi, HAL Allergie, Allergy Therapeutics, ALK Abelló, Stallergenes, Quintiles, ASIT biotech, Lofarma, AstraZeneca, GSK, Immunotek, and is a current member of the AeDA, DGHN, Deutsche Akademie für Allergologie und Klinische Immunologie, HNO-BV GPA, and EAACI. MJ reports personal fees from ALK-Abelló, Allergopharma, Stallergenes, Anergis, Allergy Therapeutics, Circassia, LETI Pharma, Biomay, HAL Allergy, AstraZeneca, GSK, Novartis, Teva, Vectura, UCB, Takeda, Roche, Janssen, Medimmune, and Chiesi. CA reports grants from Allergopharma, Idorsia, Swiss National Science Foundation, Christine Kühne-Center for Allergy Research and Education, European Commission’s Horizon’s 2020 Framework Programme, Cure, Novartis Research Institutes, AstraZeneca, SciBase, and advisory role in Sanofi/Regeneron. JB reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis, Takeda, Teva, UCB, and others from KYomed INNOV. CB has received fees for delivering lectures. IA declares personal fees from Mundipharma, ROXALL, Sanofi, MSD, Faes Farma, Hikma, UCB, and AstraZeneca. B-A reports grants and/or personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, and Mylan. AC reports grants and/or personal fees from GSK, AstraZeneca, Mylan Pharma, Boehringer Ingelheim, and Sanofi. TH reports personal fees from GSK, Mundipharma, and Onrin Pharma. J-CI received personal fees from Eurofarma Argentina, Faes Farma, and nonfinancial support from Laboratorio Casasco Argentina and Sanofi. PK has received personal fees from Adamed, Berlin Chemie Menarini, AstraZeneca, Boehringer Ingelheim, Chiesi, Lekam, Novartis, Orion, Polpharma, and Teva. DL-L reports personal fees and/or grants from Allakos, Amstrong, AstraZeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, Grüenthal, GSK, MEDA, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, UCB, Gossamer, TEVA, Boehringer Ingelheim, and the Purina institute. JM declares fees and/or grants from Sanofi-Genzyme, Regeneron, Novartis, Allakos grants, Mylan Pharma, Uriach Group, Mitsuishi-Tanabe, Menarini, UCB, AstraZeneca, GSK, and MSD. RN serves in the speaker’s bureau for Optinose and as consultant/advisory board for Sanofi, Regeneron, GSK, and AstraZeneca. YO reports personal fees and/or grants from Shionogi Co., Ltd., Torii Co., Ltd., GSK, MSD, EizaiCo., Ltd., Kyorin Co., Ltd., Tiho Co., Ltd., Yakuruto Co., Ltd., and Yamada Bee Farm. NP has received personal fees and/or grants from Novartis, Nutricia, HAL Allergy, Menarini/Faes Farma, Sanofi, Mylan/MEDA, Biomay, AstraZeneca, GSK, MSD, ASIT biotech, Boehringer Ingelheim, Gerolymatos International SA, and Capricare. OP reports grants and/or personal fees from ASIT Biotech Tools SA, Laboratorios LETI/LETI Pharma, Anergis SA, ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding BV/HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, Biomay, Circassia, MEDA Pharma/Mylan, Mobile Chamber Experts (a GA²LEN Partner), Indoor Biotechnologies, GSK, Astellas Pharma Global, EUFOREA, ROXALL, Novartis, and Sanofi Aventis. JS reports personal fees from Mylan. MHS has received grants and/or personal fees from ALL, Allergopharma, ASIT Biotech, Regeneron, Merck, Immune Tolerance Network. TZ serves as a member of the WHO-Initiative “Allergic Rhinitis and Its Impact on Asthma” (ARIA), the German Society for Allergy and Clinical Immunology (DGAKI), head of the European Centre for Allergy Research Foundation (ECARF), president of the Global Allergy and Asthma European Network (GA²LEN), and serves in the committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO). All other authors have no conflict of interest within the scope of the submitted work.
ORCID

Ludger Klimek https://orcid.org/0000-0002-2455-0192
Cezmi Akdis https://orcid.org/0000-0001-8020-019X
Mübeccel Akdis https://orcid.org/0000-0003-0554-9943
Claus Bachert https://orcid.org/0000-0003-4742-1665
Ioana Agache https://orcid.org/0000-0001-7994-364X
Alvaro A. Cruz https://orcid.org/0000-0002-7403-3871
Tari Haahtela https://orcid.org/0000-0003-4757-2156
Ken Ohta https://orcid.org/0000-0001-9734-4579
Yoshitaka Okamoto https://orcid.org/0000-0001-9734-4579
Oliver Pfaar https://orcid.org/0000-0003-4374-9639
Sanna Toppila-Salmi https://orcid.org/0000-0003-0890-6686
Mohamed H. Shanji https://orcid.org/0000-0003-3425-3463
Paola Matricardi https://orcid.org/0000-0002-2145-3776
Torsten Zuberbier https://orcid.org/0000-0002-1466-8875

REFERENCES

1. Li Q, Guan X, Wu P, et al. Early transmission dynamics in wuhan, china, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199-1207.
2. Zhu NA, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.
3. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus. classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536-544.
4. Zhang J-J, Dong X, Cao Y-Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020;75:1730-1741.
5. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418-423.
6. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506.
7. Organization WHO. www.who.int. Accessed May 02, 2020.
8. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054-1062.
9. Control ECfDPa. Rapid risk assessment: Novel coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK – sixth update https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-novel-coronavirus-disease-2019-covid-19-pandemic-increased-copy-to-clipboard2020. Accessed May 02, 2020.
10. Organization WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)2020. Accessed May 02, 2020.
11. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929-936.
12. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970-971.
13. Control ECfDPa. COVID-19 https://www.ecdc.europa.eu/en/covid-19-pandemic2020. Accessed May 02, 2020.
14. Organization WH. Coronavirus disease (COVID-19) outbreak http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-192020. Accessed May 02, 2020.
15. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102(4 Pt 1):558-562.
16. Durham SR, Leung DY. One hundred years of allergen immunotherapy: time to ring the changes. J Allergy Clin Immunol. 2011;127(1):3-7.
17. Jutel M, Van de Veen W, Agache I, Askar KA, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development. Allergol Int. 2013;62(4):425-433.
18. Dhami S, Kakourou A, Asamoah F, et al. Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy 2017;72(12):1825-1848.
19. Dhami S, Nurmatov U, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy 2017;72(11):1597-1631.
20. Klimek L, Breherl R, Hamelmann E, et al. Entwicklung der subkutanen Allergen-Immuntherapie (Teil 1): von den Anfängen zu immunologisch orientierten Therapiekonzepten. Evolution of subcutaneous allergen immunotherapy (part 1): from first developments to mechanism-driven therapy concepts. Allergo J Int. 2019;28:78-95.
21. Klimek L, Breherl R, Hamelmann E, et al. Zertifizierte Fortbildung. Entwicklung der subkutanen Allergen-Immuntherapie (Teil 2): präventive Aspekte der SCIT und Innovationen. Allergo J Int. 2019;28:107-119.
22. Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717-725.
23. Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews. Clin Transl Allergy. 2017;7:24.
24. Queisser A, Hagedorn S, Wang H, et al. Ecotropic viral integration site 1, a novel onconeogene in prostate cancer. Oncogene 2017;36(11):1573-1584.
25. Blumchen K, Trendelenburg V, Ahrens F, et al. Efficacy, safety, and quality of life in a multicenter, randomized, placebo-controlled trial of low-dose peanut oral immunotherapy in children with peanut allergy. J Allergy Clin Immunol Pract. 2019;7(2):479-5491.
26. Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet 2019;393(10187):2222-2232.
27. Dhami S, Zaman H, Varga E-M, et al. Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis. Allergy 2017;72(3):342-365.
28. Asaria M, Dhami S, van Ree R, et al. Health economic analysis of allergen immunotherapy for the management of allergic rhinitis, asthma, food allergy and venom allergy: A systematic overview. Allergy 2017;73(2):269-283.
29. Jutel M, Agache I, Bonini S, et al. International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol. 2016;137(2):358-368.
30. Meadows A, Kaambwa B, Novielli N, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assessment. 2013;17(27):vi, xi-xiv, 1-322.
31. Woehlk C, von Bülow A, Kriebbaum M, Backer V, Porsbjerg C. Allergic asthma is associated with increased risk of infections requiring antibiotics. Ann Allergy Asthma Immunol. 2018;120(2):169-176.
32. Ahmetaj L, Mehič B, Gojak R, Neziri A. The effect of viral infections and allergic inflammation in asthmatic patients on immunotherapy. Turkish J Immunol. 2018.45:323-328.
33. Iemoli E, Borgonovo L, Fusi A, et al. Sublingual allergen immunotherapy in HIV-positive patients. Allergy 2016;71(3):412-415.
34. Reuter S, Lemmermann NAW, Maxeiner J, et al. Coincident airway exposure to low-potency allergen and cytomegalovirus sensitizes for allergic airway disease by viral activation of migratory dendritic cells. PLoS Pathog. 2019;15(3):e1007595.
35. Klimek L, Kündig T, Kramer MF, et al. Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases. Allergo J Int. 2018;27(8):245-255.

36. Storni F, Zeltins A, Balke I, et al. Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergens. J Allergy Clin Immunol. 2019;145(4):1240-1253.

37. Pfaar O, Agache I, Blay F, et al. Perspectives in allergen immunotherapy: 2019 and beyond. Allergy 2019;74(Suppl 108):3-25.

38. Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 2020;17(5):533-535.

39. Akdis CA, Akdis M, Blesken T, et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest. 1996;98(7):1676-1683.

40. Jutel M, Akdis M, Budak F, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003;33(5):1205-1214.

41. Korteeka Krohn I, Shikhagaie MM, Golebski K, et al. Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications. Allergy 2018;73(4):837-850.

42. Dong X, Cao Y-Y, Lu X-X, et al. Eleven faces of coronavirus disease 2019. Allergy 2020. https://doi.org/10.1111/all.14289

43. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine. 2020.

44. Prompetchara E, Ketlow C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1-9.

45. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005;116(3):608-613.

46. Xiang J, Yan M, Li H, et al. Evaluation of Enzyme-Linked Immunoassay and Colloidal Gold- Immunochromatographic Assay Kit for Detection of Novel Coronavirus (SARS-CoV-2) Causing an Outbreak of Pneumonia (COVID-19). Woodbury, NY: Cold Spring Harbor Laboratory Press; 2020.

47. Zhang W, Du R-H, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9(1):386-389.

48. Zhou P, Yang XL, Wang XG, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv, 2020.

49. Organization WHO. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(n-cov)-infection-is-suspected-202001252020. Accessed May 02, 2020.

50. Organization WHO. Infection prevention and control of epidemic-and pandemic acute respiratory infections in healthcare care https://www.who.int/csr/bioriskreduction/infection_control/publi cation/en/. Accessed May 02, 2020.

51. Control ECDFPa. Guidance for wearing and removing personal protective equipment in healthcare settings for the care of patients with suspected or confirmed COVID-19 https://www.ecdc.europa.eu/en/publications-data/guidance-wearing-and-removing-personal-protective-equipment-healthcare-settings2020. Accessed May 02, 2020.

52. Organization WHO. Rational use of personal protective equipment for coronavirus disease 2019 (COVID-19) https://apps.who.int/iris/bitstream/handle/10665/331215/WHO-2019-nCov-IPCPPE_use-2020.1-eng.pdf2020. Accessed May 02, 2020.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Klimek L, Jutel M, Akdis C, et al. Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. Allergy. 2020;75:1546–1554. https://doi.org/10.1111/all.14336

APPENDIX 1
ARIA-MASK STUDY GROUP

Ioana Aguache, Mübeccel Akdis, Mona Al-Ahmad, Emilio Alvarez Cuesta, Hasan Arshad, Maria Cristina Artesani, Zeinab Awad, Claus Bachert, Mostafa Badr Eldin, Sergio Barba, Cristina Barbara, Eric D Bateman, Bianca Beghe, Elisabeth Bel, Karl-Christian Bergmann, David Bernstein, Leif Bjerner, Attilio Boner, Sergio Bonini, Sinitha Bosnic-Anticevich, Isabelle Bosse, Jacques Bouchard, Louis-Philippe Boulet, Fulvio Braido, Christopher Brightling, Roland Buhi, Carmen Bunu, Andrew Bush, William W Busse, Francisco Caballero-Fonseca, Davide Caimmi, Silvia Caimmi, Paulo Camargos, G Walter Canonica, Vicky Cardona, Kai-Hakon Carlsten, Warner Carr, Thomas Casale, Lorenzo Cecchi, Niels H Chavannes, Mario Alfonso Cepeda, Tomas Chivato, Ekaterine Chkhartishvili, George Christoff, Derek K Chu, Cemal Cingi, Giorgio Ciprandi, Ieva Cirule, Jaime Correia de Sousa, Maria del Carmen Costa Dominguez, André Coste, Linda Cox, Alvaro A Cruz, Adnan Custovic, Uri Darsow, Frédéric de Blay, Diana Deleanu, Pascal Demoly, Philippe Devillier, Alain Didier, Ratko Djujanovic, Maria Do Ceu Teixeira, Dejan Dokić, Ruta Dubakiene, Stephen Durham, Patrik Eklund, Yehia El-Gamal, Regina Emuzyte, Julia Esservon-Bieren, Alessandro Fiocchi, Wytske J Fokkens, Joao A Fonseca, Mina Gagi, José Luis Gálvez Romero, Blun Geminioglio, Sonya Genova, José Gereda, Maximilian Gomez, Mala Gotua, Ineta Grisle, Marta Guidacci, Maria Antonieta Guzmán, Tari Haathela, Adnan Hejjajou, Elham Hossny, Jonathan O Hourihane, Martin Hrubíško, Yunuen Huerta Villalobos, Guido Iaccarino, Carla Irani, Zhanat Ispayeva, Juan-Carlos Ivancevich, Edvardo Jares, Ewa Jassem, Erika Jensen-Jarolim, Sebastian Johnston, Guy Joos, Ki-Suck Jung, Jocelyne Just, Igor Kaidashev, Omer Kalayci, Fuat Kalyoncu, Przemyslaw Kardas, Jussi Karjalainen, Nikolai Kraltaev, Jorg Kleine-Tebbe, Ludger Klimek, Gerard Koppelman, Marek L Kowalski, Mikael Kuitunen, Piotr Kuna, Violeta Kviedariene, Amir H Abdul Latiff, Susanne Lau, Brian Lipworth, Karin C Lodrup Carlsen, Bassam Mahboub, Mika Makela, Hans-Jorgen Malling, Gailen Marshall, Pedro Martins, Mohammad Masjedi, Juan José Matta, Cem Meço, Erik Melén, Eli O Meltzer, Hans Merk, Jean-Pierre Michel, Florin Mihaltan, Neven Miculinic,
Branislava Milencovic, Youssef Mohammad, Mathieu Molimard, Mario Morais-Almeida, Ralph Mösges, Joaquim Mullol, Lars Münter, Antonella Muraro, Tihomir Mustakov, Robert Naclerio, Alla Nakonechna, Leyla Namazova-Baranova, Kristof Nekam, Laurent Nicod, Robyn O’Hehir, Ken Ohta, Yoshitaka Okamoto, Kimihiro Okubo, Brian Oliver, Pier Luigi Paggiaro, Isabella Pali-Schöll, Petr Panzner, Nikos G Papadopoulos, Hae-Sim Park, Ana Pereira, Ruby Pawankar, Oliver Pfaar, Bernard Pigéarias, Constantinios Pitsios, Davor Plavec, Wolfgang Pohl, Todor Popov, Fabienne Portejoie, Paul Potter, Lars Poulsen, Emmanuel Prokopakis, Klaus Rabe, Marysia Recto, Janet Rimmer, José Angelo Rizzo, Graham Roberts, Nicolas Roche, Antonino Romano, José Rosado-Pinto, Nelson Rosario, Lanny Rosenwasser, Philip Rouadi, Dermot Ryan, Mario Sanchez-Borges, Joaquin Sastre-Dominguez, Glenis Scadding, Elie Serrano, Nikolaos Siafakas, Estelle F Simons, Juan-Carlos Sisul, Dirceu Solé, Talant Sooronbaev, Manuel Soto-Martinez, Cristiana Stellato, Rafael Stelmach, Timo Strandberg, Charlotte Suppli Ulrik, Carel Thijs, Peter-Valentin Tomazic, Sanna Toppila-Salmi, Massimo Triggiani, Ioanna Tsiligianni, Marilyn Urrutia Pereira, Erkka Valovirta, Eric Van Ganse, Marianne van Hage, Olivier Vandenplas, Maria Teresa Ventura, Petra Vidgren, Martin Wagenmann, Dana Wallace, De Yun Wang, Susan Waserman, Magnus Wickman, Dennis Williams, Barbara Yawn, Arzu Yorgancioglu, Osman B Yusuf, Mario Zernotti, Mihaela Zidarn, Torsten Zuberbier.